SCHEDULE 13D/A: Major Shareholder BFI Co., LLC Adopts 10b5-1 Plan to Sell Phibro Animal Health Stock

BFI Co., LLC, a significant shareholder of Phibro Animal Health Corporation, has adopted a Rule 10b5-1 sales plan to sell up to 528,000 shares of Class A Common Stock for diversification purposes.

Summary

• BFI Co., LLC, controlled by Jack C. Bendheim, filed Amendment No. 22 to its Schedule 13D for Phibro Animal Health Corporation.
• As of May 30, 2025, BFI Co., LLC beneficially owns 20,225,514 shares, comprising 59,480 shares of Class A Common Stock and 20,166,034 shares of Class B Common Stock.
• This ownership represents 49.9% of the total Class A Common Stock outstanding, assuming conversion of all Class B shares, based on figures as of May 2, 2025.
• BFI Co., LLC entered into a Rule 10b5-1 sales plan with Goldman, Sachs & Co. LLC, which became effective on May 30, 2025.
• The plan authorizes the sale of up to 528,000 shares of Class A Common Stock through February 26, 2026.
• Sales are subject to certain conditions, including a minimum sale price and a limit on the number of shares that can be sold on a single trading day.
• The first possible trade date under the sales plan is September 2, 2025.
• If all shares covered by the sales plan are sold, BFI Co., LLC will continue to hold 59,480 shares of Class A Common Stock and 19,638,034 shares of Class B Common Stock.
• The stated purpose of the sales plan is to enable BFI to diversify its investment portfolio over an extended period of time.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the sale of shares by a major shareholder could be perceived negatively, the use of a Rule 10b5-1 plan for diversification over an extended period suggests a structured, non-distress sale. The stated purpose is portfolio diversification, not a lack of confidence in the company.

Positives

• The sales plan allows BFI Co., LLC to diversify its investment portfolio in a structured and pre-planned manner.
• The use of a Rule 10b5-1 plan indicates a non-discretionary sale, which can reduce market speculation regarding insider intentions.
• The amount to be sold (up to 528,000 shares) represents a modest portion of BFI's total holdings, indicating continued significant investment in the company.

Negatives

• The planned sale of up to 528,000 shares by a major shareholder could create selling pressure on Phibro Animal Health Corporation's Class A Common Stock.
• While for diversification, it still represents a reduction in the beneficial ownership percentage of a key insider group.

Risks

• Potential downward pressure on the stock price due to the sale of a significant block of shares by a major beneficial owner.
• Market perception risks if investors misinterpret the diversification sale as a lack of confidence in the company's future prospects.

Future Outlook

BFI Co., LLC plans to sell up to 528,000 shares of Phibro Animal Health Corporation's Class A Common Stock through a Rule 10b5-1 sales plan, with sales commencing as early as September 2, 2025, and continuing until February 26, 2026, or until all shares are sold, for the purpose of diversifying its investment portfolio.

Management Comments

• "Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."
• "The Sales Plan was adopted to enable BFI to sell a modest portion of its shares of Class A Common Stock (and Class B Common Stock that BFI converts to Class A Common Stock)."
• "By using a Rule 10b5-1 Sales Plan, BFI can diversify its investment portfolio over an extended period of time."

Industry Context

This filing primarily concerns a specific shareholder's investment strategy rather than broader industry trends. The adoption of a Rule 10b5-1 plan is a common practice for insiders seeking to diversify holdings in a pre-arranged, compliant manner, and does not inherently reflect on the animal health industry's performance or outlook.

Related Party Transactions

• BFI Co., LLC, a major shareholder controlled by Jack C. Bendheim (who is also the Class A Manager of BFI and likely an insider/executive of the Issuer), is entering into a sales plan to sell shares of Phibro Animal Health Corporation. This constitutes a transaction involving a related party.

Stakeholder Impact

• Shareholders: Potential for increased selling pressure on the stock price due to the planned sale of up to 528,000 shares by a significant beneficial owner.
• Management: The sales plan is a decision by a major shareholder for portfolio diversification and does not directly impact the company's operational management or strategy.

Next Steps

• Execution of the Rule 10b5-1 sales plan by BFI Co., LLC, with sales commencing as early as September 2, 2025.
• Continued monitoring of the sales plan's progress until its termination on February 26, 2026, or earlier completion.

Key Dates

Recommendation

Keywords

Phibro Animal Health Corporation, PAHC, Schedule 13D, Rule 10b5-1 Plan, Share Sale, Insider Selling, Beneficial Ownership, Class A Common Stock, Class B Common Stock, Jack C. Bendheim, BFI Co. LLC, SEC Filing, Investment Diversification